• All News
• 2022
• 2021
• 2020
• 2019
• 2017
• 2016
• 2015
• 2014

Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements

Oct 7, 2015

Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia

Sep 16, 2015

Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out

Sep 9, 2015

Xenetic Biosciences, Inc. Launches Digital Corporate Communication Channels

Sep 2, 2015

Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia

Jul 14, 2015

Xenetic Biosciences Completes $3,000,000 Bridge Note Financing

Jul 8, 2015

Xenetic Biosciences Announces Board Change

Apr 21, 2015

Xenetic Biosciences to Hold Business Update Conference Call January 20th

Jan 16, 2015

Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen® for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time

Dec 19, 2014

Xenetic Biosciences CEO Delivers “2014 – The Year in Review” Update to Investors and Stakeholders

Dec 18, 2014

• « Previous
• 1...
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• Next »